APRINOIA Secures Evvolve's Support in Capital Raise for Neurodegeneration Innovations

Evvolve Partners with APRINOIA Therapeutics for Capital Raise to Revolutionize Neurodegenerative Disease Management

Hamburg, Germany - Evvolve, a capital raising firm specializing in healthcare, AI, technology, and growth sectors, has partnered with APRINOIA Therapeutics, a company dedicated to transforming neurodegenerative disease management.

APRINOIA Therapeutics offers next-generation diagnostic tools and targeted therapeutics for patients with neurodegenerative diseases, aiming to improve early diagnosis, track disease progression, and address the root causes of these conditions.

Through this collaboration, Evvolve will leverage its investor network and capital raising expertise to fuel APRINOIA Therapeutics' groundbreaking initiatives.

"APRINOIA Therapeutics is pioneering a revolution in the early diagnosis and treatment of neurodegenerative diseases," said Vincent, Evvolve's Founder. "We are thrilled to join forces with a company that epitomises innovation and compassion, aligning perfectly with our mission."

Jamal Chraibi, Evvolve's Chief Operating Officer, added, "APRINOIA Therapeutics' commitment to advancing diagnostics and therapeutics for neurodegenerative diseases is truly inspiring. This partnership underscores our belief in APRINOIA's potential to revolutionize the field and deliver hope to patients and families affected by these devastating conditions.